December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
August 2024 in “Siberian Journal of Life Sciences and Agriculture” Melatonin and lyotritone improve hair growth and quality in white rats.
1 citations
,
August 2024 in “British Journal of Dermatology” Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
December 2025 in “International Journal of Research in Ayurveda and Pharmacy” Ayurvedic treatment successfully regrew hair in a 19-year-old with alopecia areata in 2 months.
January 2023 in “IP International Journal of Comprehensive and Advanced Pharmacology” Ayurvedic Rasayan formulations like Chyawanprash may help manage post-COVID symptoms by boosting immunity.
1 citations
,
December 1997 in “The British Journal of Psychiatry” March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
25 citations
,
January 2011 in “Pharmacognosy magazine” Nardostachys jatamansi DC compounds help promote hair growth.
40 citations
,
December 2016 in “Journal of Ovarian Research” Rutin may help treat symptoms of polycystic ovary syndrome (PCOS) in rats.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
May 2025 in “International Ayurvedic Medical Journal” Ayurvedic treatment effectively improved alopecia areata symptoms quickly and affordably.
June 2017 in “Journal of The American Academy of Dermatology” Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
January 2023 in “Cutaneous and Ocular Toxicology” 3 citations
,
November 2022 in “Frontiers in Plant Science” Microwave extraction is an effective, eco-friendly way to boost N. jatamansi's anti-Alzheimer's properties.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology”
June 2023 in “SDÜ Tıp Fakültesi Dergisi” Rutin may protect against stomach damage caused by sodium valproate.
A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with less inflammation.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
9 citations
,
March 2018 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Recognizing Jacquet's sign helps diagnose and treat traction alopecia accurately.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
Raptor and Rictor have stable expression in hair cycles, with Raptor marking stem cells and Rictor involved in hair shaft formation.
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
April 2025 in “JAAD Case Reports” Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.